A Non-interventional Post-registration Clinical Study of Efficacy and Safety of Qutenza in Patients With Post-operative Peripheral Neuropathic Pain
Phase of Trial: Phase IV
Latest Information Update: 11 Feb 2016
Price : $35 *
At a glance
- Drugs Capsaicin (Primary)
- Indications Neuropathic pain
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 05 Feb 2016 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 23 Oct 2015 Planned End Date changed from 1 Nov 2015 to 1 Dec 2015, according to ClinicalTrials.gov record.
- 23 Oct 2015 Planned primary completion date changed from 1 Sep 2015 to 1 Aug 2015, according to ClinicalTrials.gov record.